UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

European journal of cancer (1990), 2016-02, Vol.54, p.139-148

2016

Volltextzugriff (PDF)

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

European journal of cancer (1990), 2018-01, Vol.88, p.38-47

2018

Volltextzugriff (PDF)

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients

Annals of oncology, 2015-10, Vol.26 (10), p.2073-2078

2015

Volltextzugriff (PDF)

Prevalence and causes of burnout amongst oncology residents: A comprehensive nationwide cross-sectional study

European journal of cancer (1990), 2010-10, Vol.46 (15), p.2708-2715

2010

Volltextzugriff (PDF)

188 INVITED Novel Molecular Targeted Agents in NSCLC (Beyond EGFR, ALK and IGFR1)

European journal of cancer (1990), 2011, Vol.47, p.S44-S45

Soria, J.C

2011

Volltextzugriff (PDF)

Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial

Annals of oncology, 2015-08, Vol.26 (8), p.1791-1798

2015

Volltextzugriff (PDF)

127 speaker NEW THERAPEUTIC TARGETS FOR ADVANCED LUNG CANCER EGFR AND EML4/ALK

Radiotherapy and oncology, 2011, Vol.99, p.S47-S48

Soria, J.C

2011

Volltextzugriff (PDF)

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers

European journal of cancer (1990), 2009-09, Vol.45 (13), p.2333-2341

2009

Volltextzugriff (PDF)

Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours

European journal of cancer (1990), 2017-08, Vol.81, p.81-89

2017

Volltextzugriff (PDF)

Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials

Annals of oncology, 2012-01, Vol.23 (1), p.86-93

2012

Volltextzugriff (PDF)

Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?

Lung cancer (Amsterdam, Netherlands), 2014-03, Vol.83 (3), p.383-388

2014

Volltextzugriff (PDF)

Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy

Lung cancer (Amsterdam, Netherlands), 2015-09, Vol.89 (3), p.306-310

2015

Volltextzugriff (PDF)

Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials

Annals of oncology, 2007-09, Vol.18 (9), p.1477-1483

2007

Volltextzugriff (PDF)

A phase 1 study of MM-141, a novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3, in relapsed or refractory solid tumors

European journal of cancer (1990), 2016-12, Vol.69, p.S137-S138

2016

Volltextzugriff (PDF)

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

European journal of cancer (1990), 2016-12, Vol.69, p.S15-S15

2016

Volltextzugriff (PDF)

A phase Ib trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors

European journal of cancer (1990), 2016-12, Vol.69, p.S2-S3

2016

Volltextzugriff (PDF)

Phase Ib study of afatinib plus standard-dose cetuximab in patients with advanced solid tumours

European journal of cancer (1990), 2016-12, Vol.69, p.S139-S140

2016

Volltextzugriff (PDF)

A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors

European journal of cancer (1990), 2016-12, Vol.69, p.S11-S11

2016

Volltextzugriff (PDF)

First-in-human phase I dose escalation study of the Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects with advanced malignancies

European journal of cancer (1990), 2016-12, Vol.69, p.S7-S8

2016

Volltextzugriff (PDF)

Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: A clinical experience in 108 patients with metastatic breast cancer

European journal of cancer (1990), 2012-10, Vol.48 (15), p.2293-2299

2012

Volltextzugriff (PDF)

A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma

European journal of cancer (1990), 2016-12, Vol.69, p.S34-S34

2016

Volltextzugriff (PDF)

Phase 1 study of first-in-class dUTPase inhibitor, TAS-114 in combination with S-1 in patients with advanced solid tumors

European journal of cancer (1990), 2016-12, Vol.69, p.S117-S118

2016

Volltextzugriff (PDF)

First-in-human phase I trial of the anti-CEACAM5 antibody–drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848)

European journal of cancer (1990), 2016-12, Vol.69, p.S14-S15

2016

Volltextzugriff (PDF)

2631 Inclusion of patients with urothelial bladder cancer in phase 1 trials: What is the impact?

European journal of cancer (1990), 2015-09, Vol.51, p.S523-S523

2015

Volltextzugriff (PDF)

3133 Prognostic value of texture analysis and correlation with molecular profile in EGFR mutated/ALK rearranged advanced non-small cell lung cancer (NSCLC)

European journal of cancer (1990), 2015-09, Vol.51, p.S647-S648

2015

Volltextzugriff (PDF)

1 – 25 von 327

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(305)
Mit Volltextzugriff
(296)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(124)
Hematology, Oncology And Palliative Medicine
(77)
Life Sciences & Biomedicine
(73)
Humans
(58)
Oncology
(51)
Physical Sciences
(49)
Chemistry
(46)
Chemistry, Physical
(38)
Exact Sciences And Technology
(38)
Technology
(38)
Female
(34)
Male
(32)
Middle Aged
(26)
Biological And Medical Sciences
(24)
General And Physical Chemistry
(24)
Medical Sciences
(22)
Adult
(21)
Aged
(21)
Catalysis
(21)
Engineering
(20)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients

Prevalence and causes of burnout amongst oncology residents: A comprehensive nationwide cross-sectional study

188 INVITED Novel Molecular Targeted Agents in NSCLC (Beyond EGFR, ALK and IGFR1)

Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial

127 speaker NEW THERAPEUTIC TARGETS FOR ADVANCED LUNG CANCER EGFR AND EML4/ALK

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers

Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours

Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials

Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?

Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy

Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials

A phase 1 study of MM-141, a novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3, in relapsed or refractory solid tumors

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

A phase Ib trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors

Phase Ib study of afatinib plus standard-dose cetuximab in patients with advanced solid tumours

A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors

First-in-human phase I dose escalation study of the Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects with advanced malignancies

Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: A clinical experience in 108 patients with metastatic breast cancer

A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma

Phase 1 study of first-in-class dUTPase inhibitor, TAS-114 in combination with S-1 in patients with advanced solid tumors

First-in-human phase I trial of the anti-CEACAM5 antibody–drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848)

2631 Inclusion of patients with urothelial bladder cancer in phase 1 trials: What is the impact?

3133 Prognostic value of texture analysis and correlation with molecular profile in EGFR mutated/ALK rearranged advanced non-small cell lung cancer (NSCLC)

Suchergebnisse filtern